Aug 20 2026 Freshfields advised Eli Lilly and Company (“Lilly”) on its strategic research collaboration and licensing agreement with Amplitude Therapeutics to discover and develop trans-amplifying RNA (taRNA) vaccine candidates for infectious diseases. Under the agreement, Lilly will receive exclusive, target-specific rights to develop and commercialize licensed products directed to the collaboration targets.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jake Silvers
Post-Patent Expiry Royalties for Research Collaborations and Licenses: The Third Circuit Weighs in on Brulotte
According to settled Supreme Court case law, the holder of a patent may not require a licensee to pay royalties after the patent expires—the Supreme Court termed that practice “patent misuse” in Brulotte v. Thys Co. (1964) and Kimble v. Marvel Entertainment (2015). While frequently debated, the logic behind the principle is that a patent holder should not wield the leverage of a patent to extract payment from a licensee for conducting activities that other parties could do for free.
Post-Patent Expiry Royalties for Research Collaborations and Licenses: The Third Circuit Weighs in on Brulotte
According to settled Supreme Court case law, the holder of a patent may not require a licensee to pay royalties after the patent expires—the Supreme Court termed that practice “patent misuse” in Brulotte v. Thys Co. (1964) and Kimble v. Marvel Entertainment (2015). While frequently debated, the logic behind the principle is that a patent holder should not wield the leverage of a patent to extract payment from a licensee for conducting activities that other parties could do for free.
FTC Comments on USPTO’s Notice of Proposed Rulemaking Involving Patent Settlement Agreements
On June 18, 2024, the Federal Trade Commission (FTC) issued a comment (the FTC Comment) responding to the United States Patent and Trademark Office’s (USPTO) April 19, 2024 request for public comment on its notice of proposed rulemaking. The proposed rule put forward several modifications to current practices for America Invents Act (AIA) proceedings before the Patent Trial and Appeal Board (the PTAB).
FTC Comments on NIST’s Draft March-In Guidance
On February 6, 2024, the Federal Trade Commission (FTC) issued a comment (the FTC Comment) responding to the National Institute of Standards and Technology’s (NIST) request for public comment on its Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (the Draft Guidance) under the Bayh-Dole Act.
Ongoing Initiatives at the USPTO and FDA and Their Potential Impact on the Life Sciences Industry in the United States
In the past few months, proposals from the United States Patent and Trademark Office (“USPTO”) have drawn the attention of organizations, companies, and individuals in the life sciences space.
What The US-China Trade Deal Means For Drug Cos.
Law360 (January 28, 2020, 2:22 PM EST) -- On Jan. 15, the United States and China announced an economic and trade deal, the "phase one" trade agreement, which could significantly improve the ability of U.S. and non-U.S. drug companies to protect their intellectual property rights and market their innovative pharmaceutical products in China.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jake
Contact Jake, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack